Alzheimer’s Prevention: Latest News

CEOi is proud to launch its landmark report, Accelerating Alzheimer’s Prevention: A Global Imperative. The report, developed by a coalition of global leaders in government, academia, industry, and patient advocacy, outlines critical steps to drive the development and adoption of prevention therapies for Alzheimer’s Disease and Related Dementias (Alzheimer’s) on a global scale.

Alzheimer’s disease (AD) and other dementias represent one of the most significant public health crises in the U.S. and globally. Lower cost and practical prevention interventions such as active immunotherapies for AD will be critical to address the future socioeconomic global burden.

Decades of research have provided evidence that Alzheimer's disease (AD) is caused in part by cerebral accumulation of amyloid beta-protein (Aβ). In 2023, the US Food and Drug Administration gave full regulatory approval to a disease-modifying Aβ antibody for early AD. Secondary prevention trials with Aβ antibodies are underway. We summarize peer-reviewed evidence for targeting Aβ and argue that regulators should consider approving new agents working by similar mechanisms (Aβ antibodies and vaccines) based on robust amyloid lowering and reasonable safety.

The recent FDA approval of Eli Lilly’s new immunotherapy for slowing the cognitive decline of early Alzheimer’s marked another step forward in the push to develop effective therapies for this notoriously difficult disease.

Promising new vaccines are designed to be given to patients at risk of developing Alzheimer's disease. If they perform well in clinical trials, they have the potential to one day rid society of dementia

AC Immune’s phosphorylated Tau (pTau)-targeting vaccine has secured a fast track designation from the US Food and Drug Administration (FDA) to treat Alzheimer’s disease. 

Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Prothena Corporation is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that a data update for this program, using this drug to treat this patient population, will be released in 2024.

Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic?

Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives.

At least nine different vaccines are currently in clinical trials for treating Alzheimer’s disease. While none of these vaccine candidates have started Phase 3 clinical trials, the data presented by drug companies at the 16th Annual Clinical Trials in Alzheimer’s Disease (CTAD) suggests they’re a promising avenue for exploring new treatments. 

Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD).